Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.
2025 · 3rd Quarter (July 1 - Sep 30)
FRESENIUS KABI USA, LLC
Filed by CGCN GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Sep 4, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- CGCN GROUP, LLC
- Client
- FRESENIUS KABI USA, LLC
- Filing UUID
- a58ab9a0-731e-4724-9a31-46d106f56967
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.